Onconetix (NASDAQ:ONCO) Stock Price Down 22.1% – What’s Next?

Onconetix, Inc. (NASDAQ:ONCO)’s share price dropped 22.1% during trading on Friday . The company traded as low as $1.27 and last traded at $1.27. Approximately 53,879 shares changed hands during trading, a decline of 83% from the average daily volume of 317,751 shares. The stock had previously closed at $1.63.

Onconetix Trading Down 22.1 %

The business has a fifty day moving average of $4.12 and a 200 day moving average of $5.42.

Onconetix (NASDAQ:ONCO) last announced its earnings results on Thursday, August 29th. The company reported ($9.20) EPS for the quarter. The company had revenue of $0.71 million during the quarter.

Hedge Funds Weigh In On Onconetix

A hedge fund recently raised its stake in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Onconetix, Inc. (NASDAQ:ONCO) by 83.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 562,691 shares of the company’s stock after buying an additional 256,612 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned 76.04% of Onconetix worth $2,926,000 as of its most recent filing with the SEC. Institutional investors own 23.89% of the company’s stock.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.